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Abstract Anemia is a disease that is often associated
with heart failure (HF) and renal insufficiency (RI). This
unfavorable triad of conditions has been called Cardio-
Renal-Anemia Syndrome (CRS). The association of HF,
RI, and anemia is poorly reported in multicenter clinical
trials, so the pathophysiologic mechanisms and treatment
options need to be better defined. When CRS patients
develop anemia, a ‘‘perfect storm’’ often occurs: HF and RI
cause anemia which will worsen the first two conditions.
Anemia appears to be the result of complex interactions
between cardiac performance, bone marrow homeostasis,
renal dysfunction, and various drug side effects. However,
neurohormonal and inflammatory activities play a key role
in the beginning and progression of the disease. As a
consequence, endogenous erythropoietin activity dysfunc-
tion with inadequate production and tissue resistance
occurs. Despite the advances of therapy in the neurohor-
monal activation blockade, mortality and hospitalization in
HF still remain unacceptably high, suggesting that specific
comorbidity treatments could have a significant positive
prognostic impact. Anemia should be recognized as one of
the novel targets in HF treatment.
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Introduction
Anemia as well as renal insufficiency (RI) are two con-
ditions that tend to be excluded from large clinical trials.
The prevalence of anemia in multicenter studies varies
from 5 to 55%. This has to do with the clinical selection
criteria as well as with different cutoff points [1]. How-
ever, anemia has been recognized as an important
comorbidity in heart failure (HF) patients, and it appears
to be related to the worse outcome in patients with both
RI and HF. Cardio-Renal Syndrome (CRS) is often
associated with anemia [2]. This unfavorable triad of
conditions has been called Cardio-Renal-Anemia Syn-
drome (CRAS). Multiple observational studies have
clearly demonstrated an independent association between
lower hemoglobin values and an adverse clinical out-
come. Current HF guidelines do not provide specific
recommendations for the evaluation and treatment of
anemia [3]. Since the mortality in HF remains high
despite the therapeutic advances in the neurohormonal
activation blockade, anemia could represent one of the
novel therapeutic targets in HF.
Clinical impact of anemia in HF
Anemia is often associated with such unfavorable clinical
conditions as older age, diabetes, RI, and a high incidence
of atherosclerotic burden as cerebral and coronary disease
[4]. The ARIC study demonstrated that anemia in primary
prevention is related to a higher incidence of cardiovas-
cular diseases [5]. HF patients with anemia are more
likely to have a worse quality of life as they have a lower
exercise capacity, a higher NYHA classification, lower
blood pressure, hyponatremia, and the need for higher
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diuretic dosages. The Optimize-HF registry containing
information about more than 48,000 patients reported that
anemia is associated with all-cause mortality and mor-
bidity, and an increased relative risk of around 30% [6].
Similarly, Kosiborod et al. [7] demonstrated a progres-
sively worsening outcome for hematocrit values below
32%, and patients with 27% demonstrated a similar
prognostic impact as patients with an ejection fraction
lower than 25%. Two recent meta-analysis evaluating
hemoglobin levels as a continuous variable confirmed
this trend. In both studies, anemia was frequently
observed and was found in over one-third of HF patients:
the unadjusted mortality risk was OR 1.96, and after
analyzing multivariate assessments including socio-
demographic variables, medical history, drug use, and
laboratory data as parameters, anemia remained an inde-
pendent risk factor for mortality [8, 9]. These data could
be extended to patients with systolic or diastolic HF, in
fact data from the CHARM study revealed similar risk
factors for cardiovascular death and hospitalization in
both groups. Therefore, anemia was similarly present in
patients with preserved or depressed ejection fraction and
in most cases associated with RI [10]. The data reported
referred to a basal Hb level; however, a Hb decrease of
more than 1 g/dl during a follow-up period has been
independently associated with subsequent mortality and
morbidity. A Hb decrease appears also to be related to
several other variables including BNP, CRP, albumin
levels, and the glomerular filtration rate. Similar data are
reported for less serious degrees: ambulatory patients with
anemia displayed a mortality risk in 5 years of 18% with
respect to non-anemic patients. Even in this population,
anemia is associated with higher BNP levels, poor dia-
stolic function, and increased pulmonary artery pressure
[11].
Anemia and RI are often associated, but the only study
that analyzed the combination of the two diseases is the
ANCHOR Trial, evaluating 58,000 patients with HF, RI,
and anemia during a 5-year follow-up. In this study, the
independent prognostic impact of both Hb and GFR with a
progressive crude mortality risk below 11 g/dl and 44 ml/
min, respectively, was clearly demonstrated [12].
The same results regarding HF patients could include
subjects suffering from coronary artery disease: in this
setting, anemia is associated with greater coronary disease
extension and higher adverse events in stable angina as
well as in acute coronary syndromes. Moreover, anemic
coronary patients demonstrated higher mortality and
hospitalization risks [13]. In patients submitted to percu-
taneous revascularization, anemia is associated with
increased troponin and myoglobin periprocedural levels
which is likely due to the reduced levels of plasma O2
tension [14].
Compensatory mechanisms and consequences
of anemia
The mechanisms behind the increased mortality risks
observed in anemic CHF patients are not completely
understood. Anemia may lead to an increased cardiac
work, resulting from increased heart rate, stroke volume,
and workload [15]. Renal failure might be implicated
as well in the pathophysiology as a common comorbidity
in CHF. The most important compensatory mecha-
nisms caused by the reduced oxygen tension are non-
hemodynamic and hemodynamic responses, which are
shown in Table 1.
Non-hemodynamic responses to anemia include an
increase in erythropoiesis to enhance the oxygen-carrying
capacity, as well as an increase in RBC 2,3-diphospho-
glycerate that shifts the hemoglobin–oxygen dissociation
curve to the right to improve the oxygen delivery to the
peripheral tissues. The Hb–oxygen dissociation curve is
influenced by several factors: tissue acidosis and an ele-
vated diphosphoglycerate concentration which shift the
curve to the right, a decreasing Hb affinity for oxygen with
consequent improvement of the oxygen delivery [2, 16].
Since the erythropoiesis is defective in HF, the hemody-
namic responses may predominate. The hemodynamic
response is complex, depending on a delicate balance
between the vasodilation status and the neurohormonal
activation. The initial hemodynamic response to anemia is
a decrease of the vascular resistance. This decrease of the
vascular resistance causes a reduction of the systemic
blood pressure. Both mechanisms are able to trigger a
baroceptor response throughout neurohormonal activation.
The increase of the renin–angiotensin–aldosterone levels
and the sympathetic activity will lead to a peripheral
vasoconstriction, a reduction in renal blood flow and glo-
merular filtration rate, as well as salt and water retention
with a subsequent expansion of the extracellular plasma
volume. The extracellular plasma expansion associated
with vasodilation causes an early cardiac output increase.
However, after a short-term response, systemic and venous
congestion will set in, worsening the HF status [17].
Table 1 Hemodynamic and non-hemodynamic compensatory mech-
anisms of Anemia in Heart Failure
Non-hemodynamic Hemodynamic
Increase erythropoiesis
Affinity change Hb/O2 Increase LV work load and output
Reduced vascular resistance
Increased RAA activity
Reduced GFR and renal blood flow
Salt and water retention
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The cathecolamine and RAA activity associated with
sodium reuptake and the increase in water retention will
cause deleterious direct effects on the cardiac muscle: the
higher cardiac workload increases the left ventricular mass
and remodels it with a higher myocardial fibrosis deposi-
tion, myocardial disarray, and subsequent risks of
arrhythmia [18]. All these cardiac modifications could
result in worsening heart failure and have a potential
adverse outcome. Hemodynamic and neurohormonal
responses to anemia are very similar to the pathophysio-
logic mechanisms seen in HF and RI. Both diseases could
create a vicious circle where HF causes RI and both cause
anemia which will worsen both HF and RI (Fig. 1).
Causes of anemia
Although the causal relationship between HF and anemia
remains poorly defined, there are multiple potential mecha-
nisms throughout which the HF syndrome could contribute
to the development of anemia. Several potential mechanisms
may be involved, including hematinic abnormalities linked
to reduced bone perfusion, hemodilution, the inflammatory
status activity, malnutrition, malabsorption, renal insuffi-
ciency with renal blood flow modifications, as well as side
effects of drugs currently used in the treatment of HF [1, 17].
Hematinic abnormalities
Serum vitamin B12 and folic acid levels are low in just
a minority of anemic patients with HF. Similarly iron
deficiency, although insufficiently reported in the literature,
could represent a contributing factor. Gastrointestinal
bleeding from aspirin, warfarin-like agents, malignant
tumors, polyps or esophagitis, or reduced iron absorption
resulting from gastrointestinal diseases could potentially
contribute to the anemia.
Hemodilution
An expanded plasma volume is very common in HF and
RI. Hemodilution can even occur in euvolemic patients
inducing a false anemic status [18]. However, a recent
study demonstrated that a red cell deficit was present in
most of CHF patients with anemia. All systolic CHF
patients and 71% of the diastolic CHF patients presented an
expanded plasma volume. This study suggests that there is
a true red cell deficit in the majority of anemic CHF
patients [19].
Inflammatory activity
Proinflammatory cytokines such as tumor necrosis factor
(TNF)-alpha and interleukin-6 have direct effects on the
bone marrow, and are implicated in the mechanism of
chronic anemia. High levels of circulating proinflammatory
cytokines are known to be associated with greater disease
severity and worsened clinical outcomes. Elevated inter-
leukins levels lead to reduced EPO production in the kid-
neys, reduced EPO activity in the bone marrow, bone tissue
resistance to EPO (with a decrease in erythroid progenitor
cell production), and an increase in the hepcidin production
in the liver [20]. An increased production of hepcidin
reduces ferroportin in the gut, reducing iron absorption as
well as reducing iron release from iron stores in macro-
phages and liver cells. Thus, the inflammatory pathway
appears to be one of the key components for the develop-
ment of anemia as a chronic disease in HF [21, 22].
Malnutrition and malabsorption
Anemia is often associated with a poor nutritional status
and low albumin levels. Reduced absorption due to edema
of the mucosae at the gastrointestinal level caused by right-
sided heart failure could contribute to worsening anemia.
Therefore, malnutrition occurs frequently with a cachectic
status and reduced hunger stimulus.
Renal insufficiency
Renal insufficiency is common in CHF, it is associated
with an increased risk of progression of renal disease,
sudden death, and cardiovascular mortality. The renal
damage is probably mainly due to reduced renal blood flow
Pathophysiology of Fluid Retention in CHF and Anemia 
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Fig. 1 Physio–pathologic cascade during heart failure and anemia:
neurohormonal and inflammatory activation worsen renal blood flow
and increase extracellular fluid volume balance with further impair-
ment of cardiac morphology and function
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as well as intrarenal flow alteration causing hypoxic renal
damage. The increased peritubular capillary oncotic pres-
sure is associated with reduced peritubular hydrostatic
capillary pressure, which increases sodium resorption [23].
Therefore, parenchymal alterations are often associated
with HF, including tubular loss, tubulointerstitial fibrosis,
and vascular obliteration. In patients with HF and RI,
progressive renal dysfunction leads to a decrease in cir-
culating levels of erythropoietin, with a subsequent
decrease in bone marrow erythrocyte production and Hb
levels [8].
Drugs side effects
Angiotensin is a potent stimulus for the erythropoietin pro-
duction. The use of ACE inhibitors could cause a decrease in
circulating EPO levels with a modest Hb reduction. Simi-
larly, the use of Angiotensin II receptor blockers is associ-
ated with a higher incidence of anemia [24]. Beta-blockers
are also associated with a higher incidence of anemia.
Therefore, the drug blockade leads to a resistance to EPO and
a reduced genetic EPO expression [25].
In particular, a specific blockade of beta-2 adrenergic
receptors could potentially abolish both the sympatheti-
cally mediated increase in erythropoietin production and
the erythroid progenitor cell proliferation [26].
EPO and iron metabolism in CRS anemic patients
Several mechanisms are involved in the development of
anemia, even if the causal relation linking HF to anemia
remains poorly defined. Many of the above-cited mecha-
nisms are simultaneously activated, and the Hb reduction in
HF is the result of complex interactions between renal
insufficiency, inflammatory activation, bone marrow dys-
function, and increased neurohormonal activity. All these
phenomena have a common target: erythropoietin (EPO)
production, resistance, and downregulation [27]. EPO is a
glycoprotein growth factor produced primarily by the kid-
neys; it is the key component of the homeostatic system for
the regulation of the red blood cell mass and the tissue
oxygen delivery. It stimulates the erythroid cell prolifera-
tion, maturation, and differentiation. During CRS, a blunted
EPO production associated with insufficient EPO production
occurs [28]. In a pilot study by Opasich et al. [20] evaluating
patients with HF and anemia, the authors found that one-third
of the patients had renal dysfunction with consequent
reduced EPO production. On the other hand, other studies
showed that patients with increased endogenous EPO levels
had a worse outcome. However, in the same sample, there
was a lack of correlation between HB and EPO levels with
the serum levels being disproportionately low for the degree
of anemia [29, 30]. These data confirm that in HF as well as in
RI, there is a relative EPO deficency and a bone marrow
resistance to endogenous EPO. Altered EPO metabolism
causes a reduced production and activity as well as other
dysfunctions: impaired erythroid progenitor cell prolifera-
tion, reduced gene expression of EPO, altered EPO signal
transduction, and a limited availability of iron for the
erythropoiesis. Another cause of the blunted EPO response is
the decreased EPO receptor number due to their internali-
zation. All these phenomena appear to be mediated mainly
by two conditions. (1) Kidney dysfunction: EPO is mostly
produced by the kidneys, and hypoxia is the fundamental
physiologic stimulus to the EPO renal production through an
exponential increase in the number of EPO producing cells.
(2) Inflammatory cytokines have a direct cytotoxic effect on
erythroid progenitor cells and inhibit their growth. Therefore,
interleukins and TNF-alfa have been shown to disrupt multi-
ple aspects of erythropoiesis, including reduction in the renal
EPO secretion, suppression of the EPO activity on red blood
cell precursors in the bone marrow level, and the reduction in
the bioavailability of iron storage [31] (Table 2).
The other alteration involves the iron metabolism: iron is
essential for the Hb synthesis, and it’s homeostasis involves
iron absorption from the diet, iron moving from the liver, and
iron recycled from older red blood cells [32]. Hepcidin is a
protein produced by an inflammatory status, and it regulates
negatively both iron absorption from the gastrointestinal level
and iron transport by negative interaction with macrophages.
Hepcidin reduces iron gut absorption, thus reducing its bio-
availability for Hb production. Iron is recycled from senescent
blood cells and released from hemoglobin after macrophage
phagocytosis [33]. From the macrophages, iron is transported
into the plasma by transferrin that donates iron to cells through
transferring receptors.
Conclusions
Anemia is a common disease in CRS, and it is an inde-
pendent prognostic risk factor. Hb reduction may represent
Table 2 Iron and erythropoietin metabolism alterations associated
with renal dysfunction and inflammatory activation
EPO and iron metabolism
Blunted EPO production
Reduced EPO genetic expression
EPO receptors down-regulation
Alterated EPO signal transduction
Reduced iron transport and absorption
Increase Hepcidin expression mediated by inflammation
Interference between Hepcidin and ferroprotein
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the final phenomena of several problems ranging from
neurohormonal and inflammatory activation to renal blood
flow and the dysregulation of kidney structure. When CRS
patients develop anemia, a perfect pathophysiologic storm
occurs: HF and RI cause anemia which worsens the first
two conditions. Altered EPO metabolism is a key compo-
nent in this complex mechanism, and it appears mediated
by the inflammatory activity. Despite the neurohormonal
blockade and hemodynamic improvement by current ther-
apy, the neutral or negative results in clinical trials during
the last 10 years suggest that we have reached the ceiling
of benefits in HF treatment. A ‘‘holistic’’ view looking for
comorbidities (i.e. RI and anemia) could lead to a better
classification and treatment in patients with Cardio-Renal-
Anemia Syndrome.
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